Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.17    
    

[PRAECIS
Letterhead] 

October 20,
2004 

Michael
J. Keavany

10 Stoneybrook Lane

Malvern, PA 19355 

Dear
Michael, 

        It
is my pleasure to offer you the position of Senior Vice President, Sales and Marketing with PRAECIS PHARMACEUTICALS INCORPORATED, reporting directly to me. We are looking forward to
having you join our management team. 

        Base Pay—Your annual base salary will be $270,000, paid in 26 increments in the amount of $10,384.62 per pay period. 

        Signing Payment—You will receive an on-hire signing payment in the amount of $55,000 to cover the loss of your
2004 incentive bonus from your previous employer. 

        Management Bonus—You will be eligible to participate in the Company's Executive Management Bonus Plan (the "Bonus Plan"). The
targeted value of your bonus award will be 30% of your annual base salary. Your actual bonus will be based upon the attainment of performance related objectives established annually and approved by
the Board of Directors. Awards under the Bonus Plan are paid in cash. 

        Stock Options—The Chairman of the Board will recommend to the Board of Directors an award of stock options to purchase 150,000
shares of PRAECIS common stock ("Common Stock"), at a per-share exercise price equal to the fair market value of the Common Stock on the date the stock option is granted, and in accordance
with the Company's Third Amended and Restated 1995 Stock Plan (as it may be amended from time to time, the "Stock Plan"). These stock options will vest and become exercisable over a period of five
years as follows: 20% of the total grant shall vest and become exercisable on the first anniversary of your date of hire; and 1.67% of the total grant will vest and become exercisable monthly
thereafter for the subsequent 48 month-period, provided that you remain an employee of the Company at such times. Notwithstanding the foregoing, these stock options, and any additional stock
options granted to you under the Stock Plan, shall automatically become fully vested and exercisable immediately in the event that your employment is terminated upon, or within a one-year
period following, the effective date of a Change of Control (as defined below) of the Company, by (i) the Company, other than for Cause (as defined below), or (ii) you for Good Reason
(as defined below). The stock option agreement(s) between you and the Company with respect to these options, and any additional stock options granted to you under the Stock Plan, will be in the
Company's standard form, except that such stock options agreement(s) will provide for automatic acceleration of vesting and exercisability as set forth in the immediately preceding sentence, and will
also provide that immediately upon a Change of Control, the section of each such stock option agreement captioned "No Exercise of Option if Employment Terminated for Misconduct" shall automatically
cease to be of any force or effect and, accordingly, no termination of your employment with the Company upon or after a Change of Control will be, or will be deemed to be, a termination for
"Misconduct" for purposes of such stock option agreement(s). 

        Change of Control—If a Change of Control occurs and your employment with the Company is terminated upon, or within a
one-year period following, the effective date of such Change of Control by (i) the Company, other than for Cause, or (ii) you for Good Reason, you shall be entitled to a lump
sum payment equal to either (A) your annual salary for the year in which such Change of Control occurs, plus the full amount of your target award under the Bonus Plan for that year, if such
termination occurs during the first twelve months of your employment with the Company, or (B) two times the sum of (x) your annual salary for the year in which such Change of Control
occurs and (y) the full amount of your target award under the Bonus Plan for that year, if such termination occurs 

 

at
any time after the first anniversary of you employment with the Company. In addition, in the event of such termination, then for a period of either (i) one year following the effective date
of such termination, if such termination occurs during the first twelve months of your employment with the Company, or (ii) two years following the effective date of termination, if such
termination occurs at any time after the first anniversary of your commencement of employment with the Company, the Company shall, at its sole cost and expense, maintain in full force and effect for
your benefit (and the benefit of your spouse and children, if applicable) the long-term disability and medical and dental insurance coverage maintained by the Company and as in effect
immediately prior to the Change of Control or, if more favorable to you (and your spouse and children, if applicable), as in effect immediately prior to the occurrence of the first event or
circumstance constituting Good Reason; provided that if the general terms and conditions of such insurance do not permit the continued coverage of you (and of your spouse and children, if applicable)
as provided above, the Company shall, provide or arrange to provide you (and your spouse and children, if applicable) for the applicable period as provided above, at its sole cost and expense, with
such insurance coverage having benefits substantially similar (with no reduction in benefits) to those which you (and you spouse and children, if applicable) would otherwise have been entitled had the
continued coverage of you (and of your spouse and children, if applicable) as provided above been permitted under the general terms and conditions of such insurance. 

        Withholding—The Company may withhold from any amounts payable hereunder such federal, state, local or foreign taxes as shall
be required to be withheld pursuant to any applicable law or regulation. 

        Parachute Tax Treatment—In the event that any payment or benefit you receive from the Company or an affiliate (collectively,
the "Payments") would be subject to the excise tax (the "Excise Tax") imposed on "excess parachute payments" pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended (the
"Code"), then the Payments shall be reduced to the extent necessary so that no portion of the Payments is subject to the Excise Tax, provided that such reduction shall occur only if (A) the net
amount of such Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Payments) is greater than (B) the net amount of such
Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Payments and the amount of Excise Tax to which you would be subject in respect of
such unreduced Payments). Determinations with respect to the preceding sentence shall be made by the Company's auditors which were serving as such prior to the Change of Control, in consultation with
tax counsel selected by the Company. 

        Certain Definitions—For the purposes of this agreement: 

        A
"Change of Control" shall occur or be deemed to have occurred if: 

	(i)
	any
individual, entity or "person" (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act")), other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the Company, or any corporation owned directly or indirectly by the
stockholders of Company in substantially the same proportion as their ownership of stock of the Company, is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the
Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company's then outstanding securities entitled to vote generally for
the election of directors;

	(ii)
	individuals
who, as of the date hereof, constitute the Company's Board of Directors (as of the date hereof, the "Incumbent Board") cease for any reason to constitute a
majority of the Company's Board of Directors, provided that any person becoming a director subsequent to the date hereof whose election, or nomination for election by the Company's stockholders, was
approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of 

2

 

office
is in connection with an actual or threatened election contest relating to the election of the directors of the Company, as such terms are used in Rule 14a-11 of
Regulation 14A under the Exchange Act) shall be, for purposes of this agreement, considered as though such person were a member of the Incumbent Board; 

	(iii)
	the
stockholders of the Company approve a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other entity or entities
(whether or not the Company would be the surviving corporation), other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such
merger or consolidation representing (either by remaining outstanding or by being converted into or exchanged for voting securities of the surviving entity or any parent thereof), immediately after
such merger or consolidation, more than 50% of the combined voting power of the voting securities of such surviving entity or any parent thereof entitled to vote generally for the election of
directors; or

	(iv)
	the
stockholders of the Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially
all of the Company's assets. 

        "Cause"
shall mean: (i) your substantial and continuing willful failure to perform your assigned duties (other than any such failure resulting from incapacity due to injury or
physical or mental illness), which failure is not cured within 30 days after a written demand for substantial performance is delivered to you by the Company at the direction of the Company's
Board of Directors which specifically identifies the manner in which you have not substantially performed your assigned duties, and provided you have
had a reasonable opportunity, after receipt of such written demand, to be heard (and to be represented by counsel) at a meeting of the Company's Board of Directors, or (ii) (A) your
conviction of a felony (other than unintentional motor vehicle felonies) or (B) your engaging in gross misconduct which is materially and demonstrably injurious to the Company, provided (in the
case of this clause (B)) you have received written notice from the Company at the direction of the Board of Directors specifically identifying the acts or omissions constituting such gross
misconduct and you have had a reasonable opportunity, after receipt of such notice, to be heard (and to be represented by counsel) at a meeting of the Company's Board of Directors. For purposes of
this definition, no act or failure to act shall be considered "willful" unless it is done, or omitted to be done, in bad faith or without reasonable belief that the action or omission was in the best
interests of the Company. 

        "Good
Reason" shall mean: (i) any adverse and material alteration or diminution in your position, title or responsibilities as they existed immediately prior to the Change of
Control, if the Company does not remedy such alteration or diminution within 30 days following notice from you; (ii) the Company's material reduction of your annual base salary or
targeted bonus opportunity, in each case as in effect immediately prior to the Change of Control; or (iii) relocation of the Company's offices at which you are employed immediately prior to the
Change of Control which increases your daily commute by more than 50 miles on a round trip basis. 

        Temporary Housing—You will receive three (3) payments in the amount of $25,000 each to assist you in defraying the cost
of temporary living expenses, which may include: transportation between your current home and Waltham; apartment or hotel accommodations; parking and other miscellaneous related expenses. These
payments will be made according to the following schedule: 

	•
	The
first payment will be made upon hire;

	•
	The
second payment will be made upon completion of six (6) months of employment with the Company; and

	•
	The
third payment will be made upon completion of twelve (12) months of employment with the Company. 

3

 

        Relocation—Upon written acceptance of this offer, the Company will be happy to assist you in defraying your reasonable
relocation expenses. This will include the following: 

	•
	The
cost to move your personal and household effects to your permanent residence in the Boston area;

	•
	Up
to a maximum of 6% of the sale price of your principal residence to cover real estate commissions, closing costs and other related fees associated with its sale;

	•
	Reasonable
costs associated with two house-hunting trips to the Boston area; and

	•
	Reasonable
costs associated with the purchase of your new home in the Boston area to include the following:

	•
	Document
preparation fees

	•
	Inspections
required by local ordinance or by community

	•
	Survey
fees

	•
	Title
search insurance costs

	•
	Attorney
fees

	•
	Recording
fees

	•
	Appraisal
fees

	•
	Other
miscellaneous/statutory fees 

        Relocation
allowances are subject to U.S. Federal Income Tax in accordance with federal statutes. The Company will provide a tax gross-up payment for those allowances that
are taxable. 

        In
the event that you voluntarily terminate your employment with PRAECIS within twenty four (24) months from the start date of your employment, you must refund to the Company, on
or before your last day of employment, all payments made to you or on your behalf by the Company in connection with your relocation. You hereby authorize the Company to deduct all relocation moneys
you owe to the Company from any moneys the Company owes you (including your final paycheck). You understand that you must repay PRAECIS any balance remaining after that final deduction is made. 

        Benefits—PRAECIS maintains a comprehensive employee benefits program in which you will be eligible to participate. These
benefits include: health, dental, prescription, vision, life and long-term disability insurance; three weeks of vacation per year (accrued at a rate of 1.25 days per month); twelve
statutory/Company designated holidays each year; and the ability to participate in the Company's 401(k) Plan and Employee Stock Purchase Plan. 

        Contingencies—this offer is contingent upon the successful completion of: 

	•
	Execution
of the Proprietary Information and Inventions Agreement and Conflict of Interest Policy, both of which are enclosed herewith (to be signed and returned with this
Offer Letter).

	•
	Proof
of employment eligibility to be provided within three days of employment. Enclosed is an Employment Eligibility Verification Form (1-9). Please read the
form carefully and bring it and any necessary documentation with you on your first day of employment. 

        Legal Fees—The Company shall pay to you or as you direct all legal fees and expenses incurred by you or on your behalf in
seeking in good faith to obtain or enforce any benefit or right provided by this agreement or in connection with any tax audit or proceeding to the extent attributable to the application of
section 4999 of the Code to any payment or benefit provided hereunder. Such payments shall be made within five (5) business days after your delivery to the Company of written request for
payment accompanied by invoices reflecting such fees and expenses incurred as to which payment is being requested. You shall be entitled to seek specific performance of your rights under this
paragraph 

4

 

during
the pendency of any dispute or controversy arising under or in connection with this agreement, and in such event the Company will not assert that there is an adequate remedy at law. 

        Successors—This agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns
(whether direct or indirect, by purchase, merger, consolidation or otherwise). The Company will require any assignee(s) or transferee(s) of all or substantially all of assets of the Company to assume
expressly and agree to perform this agreement in the same manner and to the same extent that the Company would be required to perform it if no such assignment or transfer had taken place. As used in
this agreement, "Company" shall mean the Company as hereinbefore defined and its successors and assigns as aforesaid. This agreement is personal to you and without the prior written consent of the
Company shall not be assignable by you except by will or the laws of descent and distribution. This agreement shall inure to the benefit of and be enforceable by your personal or legal
representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If you should die while any amount would still be payable to you hereunder if you had continued to
live, all such amounts shall be paid in accordance with the terms of this agreement to your devisee, legatee or other designee or legal representative. 

        Miscellaneous—This agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without
reference to principles of conflict of laws. The captions of this agreement are not part of the provisions hereof and shall have no force or effect. This agreement may not be amended or modified
otherwise than by a written agreement executed by the parties hereto or their respective successors or assigns or, in your case, legal representative(s). No delay or omission by a party in exercising
any right under this agreement shall operate as a waiver of that of any other right. A waiver or consent given by a party on any one occasion shall be effective only in that instance and shall not be
construed as a bar or waiver of any right on any other occasion. In case any provision of this agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability
of the remaining provisions shall in no way be affected or impaired thereby. The captions of the sections of this agreement are for convenience of reference only and in no way define, limit or affect
the scope or substance of any section of this agreement. This agreement may be executed in counterparts, each of which when executed shall be deemed to be an original but which taken together shall
constitute one and the same agreement. 

        By
signing this letter, you understand that your employment with PRAECIS is at-will. Therefore, your employment can terminate, with or without cause, and with or without
notice, at any time, at your option or the Company's option, and the Company can terminate or change all other
terms and conditions of your employment, with or without cause, and with or without notice, at any time. 

        We
look forward to your joining PRAECIS and are confident that you will contribute positively to our growth. 

        Please
don't hesitate to call me if you have any questions. 

Sincerely
yours, 

PRAECIS
PHARMACEUTICALS

INCORPORATED 

	

By:	
 	

/s/  KEVIN F. MCLAUGHLIN      
 Kevin F. McLaughlin

President and Chief Operating Officer	

 

5

 

Your
signature below indicates that you have read, understand and agree to the terms and conditions of this Offer Letter. Please retain a copy of this document for your files and return the signed
original to my attention. 

Agreed
and Accepted by: 

	

/s/  MICHAEL J. KEAVANY      
 Michael J. Keavany	

 
	

Date: November 11, 2004	

 
	

Employment Start Date: November 15, 2004	

 

Enclosures

6

QuickLinks

Exhibit 10.17QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.18    
    

 
 

Summary of 2005 Compensation for
  Executive Officers and Non-Employee Directors    
    

Executive Officer Compensation  

        In January 2005, the Board of Directors of PRAECIS PHARMACEUTICALS INCORPORATED (the "Company"), upon recommendation of the Compensation Committee,
approved the 2005 compensation for the Company's executive officers. The table below sets forth 2005 compensation and potential bonus award values under the Company's Executive Management Bonus Plan
(the "Bonus Plan"), as well as certain other compensation. 

	Name and Title
	 	Annual

Salary(1)
	 	Bonus

Target

Award

Value(2)
	 	Other

Compensation

	Kevin F. McLaughlin

President and Chief Executive Officer	 	$	350,000	 	50	%	 	—
	Edward C. English

Vice President, Chief Financial Officer, Treasurer

and Assistant Secretary	 	$	208,000	 	25	%	 	—
	Marc B. Garnick, M.D.

Executive Vice President and Chief Medical

and Regulatory Officer	 	$	340,000	 	40	%	 	—
	Richard W. Wagner, Ph.D.

Executive Vice President, Discovery Research	 	$	267,500	 	30	%	 	—
	Michael J. Keavany

Senior Vice President, Sales and Marketing	 	$	270,000	 	30	%	$	50,000

	(1)
	Effective
as of January 1, 2005, with the exception of Mr. McLaughlin, whose increase was effective January 24, 2005, coincident with his appointment as Chief
Executive Officer, and Mr. Keavany, who joined the Company on November 11, 2004.

	(2)
	Represents
the target award value for 2005, as a percentage of base salary, approved by the Compensation Committee for each executive officer under the Executive Management Bonus
Plan. Actual bonuses earned for 2005 may vary from zero to 150% of the target amount, depending upon the Company's 2005 performance relative to predetermined corporate performance measures, as well as
the performance of each executive officer against predetermined individual goals.

	(3)
	Represents
payments due to Mr. Keavany during 2005 to assist in defraying the cost of certain temporary living expenses. These payments are due in two equal installments in May
and November 2005, provided Mr. Keavany is an employee at such time(s). 

        None of the Company's executive officers has an employment agreement and the executive compensation described above has been or will be (with respect to actual
bonus payments for 2005) approved by the Board of Directors, upon recommendation of the Compensation Committee, but is not otherwise set forth in a written agreement between the Company and such
executive officers. 

        Each
executive officer is a party to a letter agreement with the Company providing for certain benefits in the event of the executive's termination upon or within one year following a
change of control of the Company. These agreements are filed as exhibits to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and will be
described in more detail under "Employment Agreements/Change of Control Arrangements" in the Company's Proxy Statement for its 2005 Annual Meeting of Stockholders. 

        Each
executive officer may also be eligible for an annual option grant to purchase shares of common stock, par value $.01 per share, of the Company. Annual option grants for executive
officers generally vest and become exercisable in equal monthly installments over a three-year period from the 

date
of grant so long as the individual continues to be an employee of the Company. The amount of such annual grants, if any, will be dependent upon corporate and individual performance during 2005. 

        The
executive officers are also eligible to participate in the Company's employee benefit plans, which include health, dental, life and long-term disability insurance; three
weeks of vacation per year; twelve statutory/ Company designated holidays each year; and the ability to participate in the Company's 401(k) Plan and Employee Stock Purchase Plan. 

Non-Employee Director Compensation  

        For 2005, non-employee directors will receive the following annual compensation, which has been approved by the Company's Board of Directors and
remains unchanged from 2004: 

Cash Compensation  

	•
	Annual
Retainer of $15,000.

	•
	$1,500
for each regularly scheduled board meeting.

	•
	$1,000
for each regularly scheduled committee meeting.

	•
	$500
for any special telephonic Board or committee meeting.

	•
	The
Chairman of the Audit Committee receives a per-meeting fee of $1,000 for his attendance and participation in, on behalf of the Audit Committee, meetings with
the Company's management and Ernst and Young LLP, the Company's independent registered public accounting firm, regarding the Company's financial results and other financial and accounting matters.

	•
	Reimbursement
for reasonable expenses incurred in connection with attending board and committee meetings. 

Stock Compensation  

        Directors are eligible to receive stock options under our Third Amended and Restated 1995 Stock Plan. Non-employee directors generally receive an
annual option grant to purchase 10,000 shares of common stock, par value $.01 per share, of the Company. Each annual option grant vests and becomes exercisable in equal monthly installments over a
one-year period from the date of grant so long as the individual continues to be a member of our Board of Directors. 

QuickLinks

Exhibit 10.18

Summary of 2005 Compensation for Executive Officers and Non-Employee Directors

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}]]